One-Year Evaluation of a Targeted Medication Therapy Management Intervention for Older Adults

Ashley I Martinez, Erin L Abner, Gregory A Jicha, Dorinda N Rigsby, Lynne C Eckmann, Mark J Huffmyer, Daniela C Moga, Ashley I Martinez, Erin L Abner, Gregory A Jicha, Dorinda N Rigsby, Lynne C Eckmann, Mark J Huffmyer, Daniela C Moga

Abstract

Background: Older adults are especially susceptible to adverse effects of inappropriate medication therapy, and anticholinergic medications are common culprits for cognitive dysfunction due to their action on the central nervous system. Medication therapy management (MTM) interventions can aid in deprescribing and reducing inappropriate medication use in older adults. However, there is sparse literature on the long-term sustainability of these interventions.

Objectives: To (a) investigate whether the deprescribing of anticholinergic medications during an 8-week randomized controlled trial (RCT) of a targeted MTM intervention is sustained at 1-year postintervention follow-up and (b) compare anticholinergic utilization trends in the study population with a large sample of similar individuals not exposed to the intervention.

Methods: Participants in the targeted MTM (tMTM) RCT had normal cognition or mild cognitive impairment and were recruited from enrollees in a longitudinal study at the University of Kentucky Alzheimer's Disease Center (ADC) and thus have pertinent medical information gathered approximately annually. In this posttrial observational follow-up, sustainability of the anticholinergic deprescribing intervention was assessed in participants in the RCT, and anticholinergic medication use trends were described from the RCT baseline (which occurred immediately following an ADC visit) to the next annual visit in all participants. Mean change in anticholinergic burden from RCT baseline to the next annual visit was estimated using analysis of covariance, and participants were compared with 2 external samples. Anticholinergic burden was measured using the Anticholinergic Drug Scale (ADS). The odds of decreasing baseline anticholinergic burden and number of total and strong anticholinergic medications at the follow-up study time point was assessed using logistic regression.

Results: Of the deprescribing changes made during the initial RCT, 50% were sustained after 1 year. Participants in the tMTM trial reported decreases in the use of anticholinergic antihistamines and bladder agents (-6.5 and -4.4%, respectively), but there was no change in the use of anticholinergic agents targeted at the central nervous system. While the anticholinergic burden of RCT participants decreased over 1 year (adjusted mean ADS change [95% CI] = -0.33 [-0.72, 0.07]), it was not different than the change observed in 2 external samples at the trial center (-0.20 [-0.42, 0.02]) and nationally (-0.33 [-0.39, -0.26]). There were no statistically significant differences between trial participants and external samples in the odds of decreasing anticholinergic burden nor in decreasing the number of total, or strongly anticholinergic, medications at the 1-year follow-up.

Conclusions: This study demonstrates that the sustainability of deprescribing is limited to the period of intervention, rather than affording lasting effects even over periods as short as 1 year, which was demonstrated not only in the small group of RCT participants but also by comparison with external groups. Future work should extend the duration of intervention and follow-up periods for MTM interventions to allow further insights regarding the sustainability of deprescribing efforts in older adults.

Disclosures: The original trial was supported by a pilot study award from the University of Kentucky Center for Clinical and Translational Sciences (UL1TR000117). Additional support for this study was provided by the National Institutes of Health/National Institute on Aging (R01 AG054130). Jicha reports contract research for Esai, Biohaven, Alltech, Suven, Novartis, and Lilly. The other authors have nothing to disclose.

Conflict of interest statement

The original trial was supported by a pilot study award from the University of Kentucky Center for Clinical and Translational Sciences (UL1TR000117). Additional support for this study was provided by the National Institutes of Health/National Institute on Aging (R01 AG054130). Jicha reports contract research for Esai, Biohaven, Alltech, Suven, Novartis, and Lilly. The other authors have nothing to disclose.

Figures

FIGURE 1
FIGURE 1
Percentage of Change in Anticholinergic Medication Classes
FIGURE 2
FIGURE 2
Adjusted OR and 95% CI for Decreasing Anticholinergic Measure

References

    1. Siegel S. An introduction to the Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Health Care Law Mon. 2004;Jan:3-14.
    1. Smith M, Bates DW, Bodenheimer T, Cleary PD.. Why pharmacists belong in the medical home. Health Aff (Millwood). 2010;29(5):906-13.
    1. Maracle HL, de Oliveira DR, Brummel A.. Primary care providers’ experiences with pharmaceutical care-based medication therapy management services. Innov Pharm. 2012;3(1, Article 72). Available at: . Accessed March 1, 2020.
    1. American Pharmacists Association, National Association of Chain Drug Stores Foundation. Medication therapy management in pharmacy practice: core elements of an MTM service model (version 2.0). J Am Pharm Assoc (2003). 2008;48(3):341-53.
    1. Bluml BM. Definition of medication therapy management: development of professionwide consensus. J Am Pharm Assoc (2003). 2005;45(5):566-72.
    1. Lau DT, Kasper JD, Potter DEB, Lyles A, Bennett RG.. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch Intern Med. 2005;165(1):68-74.
    1. Farrell B, Szeto W, Shamji S.. Drug-related problems in the frail elderly. Can Fam Physician. 2011;57(2):168-69.
    1. Gu Q, Paulose-Ram R, Burt V, Kit B.. Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. NCHS data brief, no. 177. National Center for Health Statistics. 2014. Available at: . Accessed March 1, 2020.
    1. Kallio SE, Kiiski A, Airaksinen MSA, et al. . Community pharmacists’ contribution to medication reviews for older adults: a systematic review. J Am Geriatr Soc. 2018;66(8):1613-20.
    1. Page AT, Clifford RM, Potter K, Schwartz D, Etherton-Beer CD.. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;82(3):583-23.
    1. Rankin A, Cadogan CA, Patterson SM, et al. . Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018. Sep 3;9:CD008165.
    1. 2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019;67(4):674-94.
    1. Ancelin ML, Artero S, Portet F, Dupuy A-M, Touchon J, Ritchie K.. Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study. BMJ. 2006;332(7539):455-59.
    1. Kachru N, Carnahan RM, Johnson ML, Aparasu RR.. Potentially inappropriate anticholinergic medication use in older adults with dementia. J Am Pharm Assoc (2003). 2015;55(6):603-612.
    1. National Institute on Aging. Alzheimer’s Disease Research Centers. 2018. Bethesda, MD. Available at: . Accessed March 1, 2020.
    1. Morris JC, Weintraub S, Chui HC, et al. . The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord. 2006;20(4):210-216.
    1. Moga DC, Abner EL, Rigsby DN, et al. . Optimizing medication appropriateness in older adults: a randomized clinical interventional trial to decrease anticholinergic burden. Alzheimers Res Ther. 2017;9(1):36.
    1. Llewellyn-Bennett R, Bowman L, Bulbulia R.. Post-trial follow-up methodology in large randomized controlled trials: a systematic review protocol. Syst Rev. 2016;5(1):214.
    1. Besser L, Kukull W, Knopman DS, et al. . Version 3 of the National Alzheimer’s Coordinating Center’s Uniform Data Set. Alzheimer Dis Assoc Disord. 2018;32(4):351-58.
    1. Carnahan RM, Lund BC, Perry PJ, Pollock BG, Culp KR.. The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity. J Clin Pharmacol. 2006;46(12):1481-86.
    1. Salahudeen MS, Duffull SB, Nishtala PS.. Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: a systematic review. BMC Geriatr. 2015;15:31.
    1. Lozano-Ortega G, Johnston KM, Cheung A, et al. . A review of published anticholinergic scales and measures and their applicability in database analyses. Arch Gerontol Geriatr. 2020;87:103885. Available at: . Accessed March 8, 2020.
    1. Viswanathan M, Kahwati LC, Golin CE, et al. . Medication therapy management interventions in outpatient settings. Report no.: 14(15)-EHC037-EF. Agency for Healthcare Research and Quality. 2014. Available at: . Accessed March 1, 2020.
    1. Campins L, Serra-Prat M, Gózalo I, et al. . Randomized controlled trial of an intervention to improve drug appropriateness in community-dwelling polymedicated elderly people. Fam Pract. 2017;34(1):36-42.
    1. Hanlon JT, Weinberger M, Samsa GP, et al. . A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy. Am J Med. 1996;100(4):428-37.
    1. Olsson IN, Runnamo R, Engfeldt P.. Drug treatment in the elderly: an intervention in primary care to enhance prescription quality and quality of life. Scand J Prim Health Care. 2012;30(1):3-9.
    1. Taylor CT, Byrd DC, Krueger K.. Improving primary care in rural Alabama with a pharmacy initiative. Am J Health Syst Pharm. 2003;60(11):1123-29.
    1. Health World Organization. Patient Engagement. Geneva: World Health Organization; 2016. Available at: . Accessed March 1, 2020.
    1. American Pharmacists Association. Pharmacists role in promoting medication adherence. In: Report of the 2015 APhA House of Delegates. J Am Pharm Assoc. 2015;55(4):365.
    1. Boustani M, Campbell N, Munger S, Maidment I, Fox C.. Impact of anticholinergics on the aging brain: a review and practical application. Aging Health. 2008;4(3):311-20.
    1. Lampela P, Lavikainen P, Garcia-Horsman JA, Bell JS, Huupponen R, Hartikainen S.. Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: a population-based study. Drugs Aging. 2013;30(5):321-30.
    1. Rudolph JL, Salow MJ, Angelini MC, McGlinchey RE.. The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med. 2008;168(5):508-13.
    1. Holmes HM, Todd A.. The role of patient preferences in deprescribing. Clin Geriatr Med. 2017;33(2):165-75.
    1. Martin P, Tannenbaum C.. A realist evaluation of patients’ decisions to deprescribe in the EMPOWER trial. BMJ Open. 2017;7(4):e015959.
    1. Health Care AHRQ Innovations Exchange. Implementation of a medication therapy management intervention in ambulatory care settings: experiences and lessons learned from the MyRx Pilot. 2016. Available at: . Accessed March 1, 2020.
    1. Moga DC, Jicha GJ.. The INCREASE Study—Delaying the onset of Alzheimer’s symptomatic expression. Clinical Identifier: NCT02849639. 2016. Available at: . Accessed March 1, 2020.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj